News | May 14, 2024
Bayer Q1 2024 net income drops 8.2% to € 2 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
The project funding will be done through a mix of internal accruals and debts.
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Subscribe To Our Newsletter & Stay Updated
